5 Key Takeaways

• 1

  AdoGel-semaglutide is a novel monthly injectable formulation showing promising results in preclinical studies.

• 2

  The formulation utilizes a hydrogel platform for sustained release of semaglutide over a one-month period.

• 3

  AdoGel consists of cross-linked degradable polymers and is injected using a 25-gauge needle.

• 4

  In a rat study, the formulation demonstrated limited burst release and regular release over one month.

• 5

  The product was well-tolerated, with no inflammatory reactions observed during the treatment period.